One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

All news / March 2021

Archive

✕

15 marca 2021

2193

DolPHIN-2: Final follow-up of pregnant women and babies after 72 weeks

DolPHIN-2: Final follow-up of pregnant women and babies after 72 weeks

We’ve known for some time that late initiation of HIV treatment in pregnant women can complicate control of the virus and increase the risk of vertical HIV transmission. The DolPHIN-2 study looked to analyse the efficacy and safety of dolutegravir (DTG) and efavirenz (EFV) ...

15 marca 2021

1721

Several European countries halt vaccination despite reassurance from health regulators

Several European countries halt vaccination despite reassurance from health regulators

Ireland, Netherlands and Germany have joined a growing number of European countries who have delayed, or halted, the rollout of the AstraZeneca (AZ) COVID-19. Ireland’s recommendation was issued by the countries Deputy Chief Physician, Dr Ronan Glynn citing research from ...

15 marca 2021

1575

WHO to host online workshops on updated HIV guidelines

WHO to host online workshops on updated HIV guidelines

The World Health Organisation (WHO) is to run a series of online workshops around their updated guidelines for HIV treatment and service delivery. The broadcasts will run for two days: March 17th from 14:00 to 16:30 GMT and March 18th 10:00 to 12:30 GMT. Seminars will be ...

15 marca 2021

1552

Gilead and Merck announce collaboration to develop HIV treatments using Lenacapavir and Islatravir

Gilead and Merck announce collaboration to develop HIV treatments using Lenacapavir and Islatravir

Today, March 15th, Gilead Sciences and Merck (known as MSD outside US and Canada) announced an agreement to jointly develop and commercialise long-acting HIV treatments based on their recently developed agents. Last week at CROI 2021 Gilead presented data on their capsid ...

10 marca 2021

1535

Vaginal PrEP ring could offer three months of HIV protection

Vaginal PrEP ring could offer three months of HIV protection

A new vaginal ring that slowly releases a pre-exposure prophylaxis (PrEP) drug could protect people with vaginas from HIV for up to three months according to new trial data. The trial, conducted by U.S. National Institutes of Health-funded Microbicide Trials Network (MTN), ...

10 marca 2021

1718

ViiV’s new maturation inhibitor shown safe & effective in Phase IIa study

ViiV’s new maturation inhibitor shown safe & effective in Phase IIa study

This week, at CROI 2021, ViiV Healthcare presented data from their Phase IIa ‘Proof of concept’ study into a new investigational maturation inhibitor (GSK3640254) designed to treat HIV in adults. The Phase IIa trial was divided into two parts to evaluate the antiviral ...

10 marca 2021

3321

First-in-class capsid inhibitor, Lenacapavir, shows promise for treatment of resistant HIV

First-in-class capsid inhibitor, Lenacapavir, shows promise for treatment of resistant HIV

Gilead Sciences’ new antiretroviral agent, lenacapavir (LEN) (GS-6207), is the first in a new class of long-acting HIV capsid (HIV protein) inhibitors. There are a number of clinical trials currently underway investigating LEN as an option for the treatment and prevention ...

9 marca 2021

1858

Dolutegravir in combination with an NRTI proves effective even in face of resistance

Dolutegravir in combination with an NRTI proves effective even in face of resistance

Data presented at CROI 2021 this week has shown that dolutegravir, when used in combination with two NRTI agents, provides effective viral suppression – even in NRTI-resistant patients. The World Health Organisation (WHO) recommends dolutegravir (DTG) with two NRTIs as ...

8 marca 2021

1814

Once-yearly HIV dosing a step closer with new Merck data

Once-yearly HIV dosing a step closer with new Merck data

Merck, also known as MSD outside North America, presented data today on a new first-in-class compound that when used in an implant could lead to once-yearly HIV treatment. Islatravir is an investigational Nucleoside Reverse Transcriptase Translocation Inhibitor (NRTTI) ...

8 marca 2021

1871

Gilead’s Biktarvy provides high-efficacy and durable viral suppression in Phase III trials

Gilead’s Biktarvy provides high-efficacy and durable viral suppression in Phase III trials

Gilead Sciences have announced new long-term data from two Phase III trials (Study 1489 and Study 1490) of their all-in-one pill Biktarvy – comprising of bictegravir 50 mg, emtricitabine 200 m and tenofovir alafenamide 25 mg. The data demonstrated “sustained efficacy” and ...

1 2 3